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Abstract Combining Lipinski’s rule with the docking and
steered molecular dynamics simulations and using the
PubChem data base of about 1.4 million compounds, we
have obtained DNA dyes Hoechst 34580 and Hoechst
33342 as top-leads for the Alzheimer’s disease. The bind-
ing properties of these ligands to amyloid beta (Ab) fibril
were thoroughly studied by in silico and in vitro experi-
ments. Hoechst 34580 and Hoechst 33342 prefer to locate
near hydrophobic regions with binding affinity mainly
governed by the van der Waals interaction. By the Thio-
flavin T assay, it was found that the inhibition constant
IC50 & 0.86 and 0.68 lM for Hoechst 34580 and Hoechst
33342, respectively. This result qualitatively agrees with
the binding free energy estimated using the molecular
mechanic-Poisson Boltzmann surface area method and all-
atom simulations with the AMBER-f99SB-ILDN force
field and water model TIP3P. In addition, DNA dyes have
the high capability to cross the blood brain barrier. Thus,
both in silico and in vitro experiments have shown that
Hoechst 34580 and 33342 are good candidates for treating
the Alzheimer’s disease by inhibiting Ab formation.
Keywords Alzheimer’s disease  DNA dyes  Hoechst
34580  Hoechst 33342  Drug design  Amyloid beta fibril
Introduction
Alzheimer’s disease (AD) is one of the most common
forms of dementia [1]. Clinically it is defined as a pro-
gressive decline in memory, language and other cognitive
functions. AD is the sixth-leading cause of death in the
United States and total payments for patients with AD and
other dementias are estimated at $226 billion in 2015 [2]
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posing huge burden to the society. Despite intense research
during many decades, the problem of finding efficient
drugs for AD remains challenging. Available drugs which
are acetylcholinesterase inhibitors and N-methyl-D-aspar-
tate (NMDA) receptor antagonists can treat some symp-
toms but not cure the disease.
In order to design potential drugs for a given disease one
has to know the corresponding target but such a target for
AD remains largely uncertain as the cause of AD has not
been disclosed yet [3]. There are about twenty hypotheses
concerning AD mechanisms [4], but recent experimental
evidences strongly support the amyloid cascade hypothesis
[5] positing that AD is associated with progressive intra-
cerebral accumulation of beta amyloid (Ab) peptides [6]. In
addition, oligomers are presumably more toxic that mature
fibrils [7, 8]. Because Ab peptides are generated by the
proteolytic cleavage of amyloid precursor protein (APP) by
b- and c-secretases, AD can be cured by either blocking
activity of these secretases or preventing Ab aggregation.
In the latter case Ab oligomers or fibrils become the drug
target. Following this strategy a lot of potential Ab inhi-
bitors have been identified including short peptides [9],
nutraceuticals [10–13], polyamines [14, 15], metal chela-
tors [16], derivatives of vitamin K3 [17], RNA aptamers
[18], osmolytes [19], and other compounds [15, 20, 21].
In the present paper, we have carried out the multi-step
screening of Ab aggregation inhibitors from data basic
PubChem [22] (http://pubchem.ncbi.nlm.nih.gov) using the
Lipinski’s rule [23, 24] in combination with the molecular
docking and steered molecular dynamic (SMD) simula-
tions. From predicted top-leads for Ab40 and Ab42 fibrils
we succeeded to purchase DNA dyes Hoechst 34580 and
Hoechst 33342 for in vitro experiment. Using the Thio-
flavin T (ThT) assay the inhibition constant IC50 was
found to be equal 0.86 and 0.68 lM for Hoechst 34580 and
Hoechst 33342, respectively. This result is consistent with
our estimation of the absolute binding free energy by the
molecular mechanic Poisson–Boltzmann surface area
(MM-PBSA) [25] method which is more accurate than the
docking method. In addition, the QSAR analysis revealed
that both DNA dyes are capable to easily cross the blood
brain barrier (BBB) implying that they are good candidates
for AD treatment.
Materials and methods
Data base of ligands and receptors
Screening of drug candidates has been performed using
about 1.4 million compounds from Collaborative Drug
Discovery in PubChem [22] (see http://pubchem.ncbi.nlm.
nih.gov). Concerning the target (receptor) we chose the
structural model of Ab40 and Ab42 fibrils. For Ab40 fibril,
the model of truncated fragment Ab9-40 which is available
in the Protein Data Bank with PDB ID: 2LMN [26] with
the 8 first disordered residues neglected. This structure has
two layers each of which contains 6 strands numbered as
A-F and G-L (Figure S1 in Supporting Information (SI)). A
full molecular structural model for Ab40 fibril is the three-
fold-symmetric (PDB ID: 2M4J [27]) containing 9 chains
(Figure S1). For Ab42 fibril, the structure of truncated
fragment Ab17-42 (PDB ID: 2BEG_ENREF_25 [28]),
which is a model built basically on mutagenesis and H/D
exchange experiments, and the solid-state NMR structures
of Ab11-42 (PDB ID 2MXU [29]) were employed
(Figure S1).
Lipinski’s rule
First, ligands were virtually screened by Lipinski’s rule of
five [23]. It sets for drug-like properties [23, 24] as
molecular weight from 0 to 500 Da, xlogP from 0 to 5, the
number of donor hydrogen bonds is from 0 to 5, and the
number of acceptor hydrogen bonds is from 0 to 10. The
application of Lipinski’s rule reduced the whole set of
about 1.4 million compounds to 5372 compounds (Fig. 1).
Docking method
Autodock Tool 1.5.4 [30] was used to prepare PDBQT file
for docking ligands to targets 2LMN, 2BEG, 2MXU, and
2M4J. The docking simulation was performed using the
Autodock Vina version 1.1 [31]. For global search, the
exhaustiveness was set to 400 which is enough for obtaining
reasonable results. Twenty binding modes have been gen-
erated starting from random configurations of ligand which
had fully flexible torsion degrees of freedom. Because the
binding site of Ab fibrils was not a priori known to cover the
whole fibril the boxes of grid dimensions
4.7 9 5.3 9 7.4 nm (2LMN), 2.9 9 4.6 9 25 nm (2BEG),
5.3 9 4.2 9 6.5 nm (2MXU) and 9.2 9 9.2 9 3.5 nm
(2M4J) were chosen. The dynamics of receptor was
neglected. The lowest binding energy DEbind obtained in the
best docking mode was chosen as a scoring function for
selecting top ligands. Here we selected only those ligands
which haveDEbind less than-10.0,-8.0 and-9.0 kcal/mol
for targets 2LMN, 2BEG, and 2MXU, respectively.
Molecular dynamic (MD) simulation
To estimate the binding free energy by the MM-PBSA
method, the molecular dynamics simulation was carried out
with the AMBER-f99SB-ILDN force field [32] and water
model TIP3P [33]. The rationale for our choice of
AMBER-f99SB-ILDN is that this force field, as shown by
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previous work [9, 34–36], provided reasonable results on
binding affinity of small molecules to amyloid fibrils. The
GAFF force field [37] was used for parameterization of
ligands Hoechst 33342 and Hoechst 34580. Restrained
electrostatic potential [38] (RESP) point charges were
assigned to ligand atoms by the Antechamber package [39]
based on electrostatic potential (ESP) calculated by Gaus-
sian09 package [40] at the B3LYP/6-31G* level. Names,
types atoms, masses and charges of atoms used in the
simulation for Hoechst 33342 and Hoechst 34580 are listed
in Table S1 and S2 in SI.
The fibril-ligand complex was placed in the
9.3 9 9.3 9 9.3 (2LMN), 6.8 9 6.8 9 6.8 (2BEG),
7.6 9 7.6 9 7.6 (2MXU) and 11.1 9 11.1 9 11.1 nm3
(2M4J) cubic boxes containing about 78,500, 31,400,
41,448 and 136,200 water molecules with 1 nm distance
between the box and solute. The van der Waals (vdW)
forces were calculated with a cutoff of 1.4 nm, while the
long-range electrostatic interaction was computed by the
particle-mesh Ewald summation method [41]. Equations of
motion were iterated by a leapfrog algorithm [42] with a
time step 2 fs. The overall charge of the systems was set to
zero by adding 12, 5, 8 and 27 Na? ions to 2LMN, 2BEG,
2MXU and 2M4J, respectively. After minimization by the
steepest descent method, the position-restrained MD sim-
ulations were performed for 500 ps to let water molecules
to move into the active site. The equilibration was reached
by coupling with temperature and pressure. Constant
temperature 300 K was kept using Langevin dynamics with
the collision frequency of 2.0 ps-1. The Berendsen barostat
[43] was used to maintain the pressure at 1 atm and 300 K
with the pressure relaxation time of 1.0 ps.
Steered molecular dynamics
The steered molecular dynamics (SMD) method was
developed to study mechanical unfolding of biomolecules
[44, 45] and ligand unbinding from receptor along a given
direction [46]. Recently, it has been shown that this method
is as accurate as the MM-PBSA method but computation-
ally much less demanding [47, 48]. Because the predictive
power of the docking method is limited the SMD method
was employed to refine docking results as a next step in the
multi-step screening procedure. Overall, an spring with
spring constant k is attached to a dummy atom at one end
and to the first heavy atom of ligand in the pulling direction
at the another end. Moving along the pulling direction with
a constant loading rate v the dummy atom experiences
elastic force F = k(Dx - vt), where Dx is the displacement
of pulled atom from the starting position. We have chosen
the spring constant k = 600 kJ/(mol nm2) which is a typ-
ical value for cantilever used in AFM experiment [49]. As
in our previous works [48, 50, 51], the loading speed was
set equal v = 5 nm/ns. This choice of parameters k and
v was proved as reasonable for pulling experiment [51]. All
Ca-atoms of receptor were restrained to keep the receptor
almost at the same place but still maximally maintain its
flexibility.
We determined possible pathways of ligands by using
CAVER 3.0 [52], Pymol plugin, and chose the easiest path
for ligand to exit from receptor as the pulling direction
[50]. After equilibration, to completely pull the ligand out
of the binding site, 500 ps SMD runs were carried out in
NPT ensemble. To obtain reliable results five independent
trajectories were performed with different random seeds. In
the SMD method the maximum force Fmax in the force-
extension/time profile was chosen as a score for binding
affinity, i.e. the larger is Fmax, the stronger is the ligand
binding.
MM-PBSA method
The MM-PBSA method [25] was used to estimate the
binding free energy DGbind of DNA dyes to targets 12Ab9-
Fig. 1 Multi-step screening procedure. From 1.4 million compounds
we keep only 5372 compounds satisfying the Lipinski’s rule for drug-
like ligands. The further screening by docking method and require-
ment that drug candidates should have the binding energy
DEbind\-9.0 kcal/mol and lg(BB)[ 0 give the set of 27 ligands
for 2MXU, and binding energy DEbind\-10.0 kcal/mol and
lg(BB)[ 0 give the set of 36 ligands for 2LMN. Imposing that
candidates should have DEbind\-8 kcal/mol and lg(BB)[ 0 we
obtained 11 ligands for 2BEG, respectively. Applying the SMD
method to the set of 36 ligands we obtained 15 top leads for 2LMN
and 13 top leads for 2MXU, while this method was just used for re-
ranking 11 top leads for 2BEG
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40 (2LMN), 9Ab1-40 (2M4J), 5Ab17-42 (2BEG), and
8Ab11-42 (2MXU). More details on this method may be
found elsewhere [53, 54]. Typically, DGbind is given by the
following expression:
DGbind ¼ DEelec þ DEvdW þ DGsur þ DGPB  TDS; ð1Þ
where DEelec and DEvdW are contributions from electro-
static and vdW interactions, respectively. DGsur and DGPB
are nonpolar and polar solvation energies. The entropic
contribution TDS was estimated using the normal mode
approximation. Snapshots collected in equilibrium and
Eq. (1) were used to compute DGbind.
Blood brain barrier
One of the most important requirements for AD drug
candidates is that they should be able to cross the blood
brain barrier (BBB) [55] which is created by the brain
capillary endothelium. The logarithm base 10 of the ratio
of the ligands concentration in the brain to that in the
blood, log(BB), is a measure of capability of a given ligand
to pass BBB. This quantity is estimated by the QSAR
(quantitative structure–activity relationship) approach [56].
The sever preADMET [57, 58] (see http://preadmet.bmdrc.
org/) was used to calculate log (BB).
Measures used in data analysis
The backbone root mean square deviation (RMSD), com-
puted using the Gromacs 5.1 package, was used to measure
the deviation of structures of the receptor from its initial
configuration. A hydrogen bond (HB) was formed provided
the distance between donor D and acceptor A is less than
3.5 A˚, the H-A distance is less than 2.7 A˚ and the D-H-A
angle is larger than 135 degrees.
Ab preparation
Ab was prepared as described in previous literatures [10].
Briefly, Ab42 peptide (Biopeptide, San Diego, CA) was
dissolved in 50 % acetonitrile, divided into aliquots, lyo-
philized overnight, and stored at -80 C. Before experi-
ments, Ab42 was dissolved in hexafluoroisopropanol
(HFIP) in 1 mg/mL. The sample was mixed vigorously
using a vortex for 5 s and then sonicated for 5 min. After
quiescent for 1 h, the HFIP was evaporated in vacuum and
Ab peptides were dissolved by anhydrous dimethyl sul-
foxide (DMSO) in 60 mg/mL and then diluted in 10 mM
phosphate buffer, pH 7.4. The final Ab concentration was
50 lM in ThT assays and 25 lM in fluorescence titration.
Compounds preparation
As seen below, Hoechst 34580 and Hoechst 33342 are
among the top leads revealed by molecular simulation.
They were purchased from Sigma-Aldrich (St. Louis, MD)
and were used without purification. Compounds were dis-
solved respectively in DMSO at 10 mM as stocks. In ThT
assays, the desired concentrations of the compounds were
serial diluted in DMSO. In fluorescence titration assay,
10 mM compounds were diluted with 10 mM phosphate
buffer (pH 7.4) to 5 mM and proceed for titration.
Structures of Hoechst 34580 and Hoechst 33342
In this study, Hoechst 34580 and Hoechst 33342 which are
commercially available cell-permeable fluorescent dye for
staining DNA and nuclei (Fig. 2). They are identical except
the last fragment NCH3CH3 for Hoechst 34580 and
OCH2CH3 for Hoechst 33342.
Fig. 2 2D structures of Hoechst
34580 and Hoechst 33342
642 J Comput Aided Mol Des (2016) 30:639–650
123
ThT assay
Ab42 fibrillization was measured using a Thioflavin T (ThT)
assay. The compounds, from 1.22 lM to 10 mM, were
prepared in DMSO and 0.4 ll of each was added to 384 well
black plate. Each concentration was prepared in independent
triplicates and a solvent control was included. Ab42 solution
at 50 lM in 39.6 ll was prepared with addition of 5 lM
ThT. The samples were incubated at 37 C with agitation for
1 min every hour. ThT fluorescence was monitored using an
ELISA microplate reader SpectraMax M5 (Molecular
Devices, Sunnyvale, CA) at an excitation wavelength of
442 nm and an emission wavelength of 485 nm. Measure-
ments from independent triplicate trials were averaged and




After the first virtual screening step by Lipinski’s rule, the
number of compounds is reduced to 5372 (Fig. 1). The
Autodock Vina [31] method was then applied to dock this
set to targets 2LMN, 2BEG, and 2MXU. We did not per-
form the similar docking simulation for the whole ligand
set to 2M4J because both 2M4J and 2MXU are solid state
NMR structures. However, the docking of DNA dyes was
carried for the target 2M4J as well. The binding energies
DEbind, obtained in the best docking modes for 5327
ligands, vary from -0.6 to -11.4 (2LMN), -1.2 to -8.8
(2BEG), and -1.4 to -11.9 kcal/mol (2MXU) (Figure S2
in SI). There are 96 compounds that have the binding
energy lower than -10 kcal/mol for 2LMN, 55 compounds
have DEbind\28.0 kcal/mol for 2BEG and 57 com-
pounds have DEbind\-9.0 kcal/mol for 2MXU. Loca-
tions of these compounds in fibrils are presented in
Figure S3 in SI. As expected Ab do not have well defined
binding sites because ligands locate either inside or
between two layers.
Because we succeeded to purchase DNA dyes Hoechst
34580 (CID: 448202) and Hoechst 33342 (CID: 1464) for
in vitro experiment, we consider them in more detail. Their
binding poses in 2LM, 2BEG, 2M4J and 2MXU are shown
in Fig. 3. Except full length fibril 9Ab1-40 (2M4J), derived
from a human patient, Hoechst 34580 and Hoechst 33342
have nearly the same binding positions in the remaining
targets. The DNA dyes are located between two layers near
Fig. 3 Binding poses of dyes
Hoechst 34580 and Hoechst
33342 in 2LM, 2BEG, 2M4J
and 2MXU. The structures were
obtained by the docking method
J Comput Aided Mol Des (2016) 30:639–650 643
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the turn region of 2LMN, inside 2MXU, partially inside
2BEG and outside 2M4J fibrils (Fig. 3). Moreover, for a
given target their binding energies are very close to each
other (Tables S3–S5). This also holds for 2M4J, where two
ligands bind to different places but DEbind = -7.27 and
-7.15 kcal/mol for Hoechst 34580 and Hoechst 33342,
respectively. These results, as shown below, are consistent
with the fact that they also have close rupture forces
obtained by MD simulations and close binding free ener-
gies. The minor difference in their binding affinity is pre-
sumably due to high structural similarity (Fig. 2).
In docking, Hoechst 33342 forms one hydrogen bond
(HB) with 2LMN, but none HB was found for 2BEG,
2MXU and 2M4J, while Hoechst 34580 does not have
hydrogen binding with four targets (Fig. 4). Because the
binding affinity of these compounds is high the poor HB
networks indicate that the number HBs alone is not suffi-
cient enough to describe the binding affinity of these
complexes.
For 2LMN, Hoechst 33342 has 11 side chain (SC)
contacts with residues Val39(K), Gly38(J), Ile31(D),
Gly38(I), Val40(I), Gly29(C), Ile31(C), Gly38(H),
Lys28(B), Gly29(B) and Gly29(A), whereas Hoechst
34580 forms 15 SC contacts with Val39(K), Gly29(E),
Ile31(D), Gly38(I), Ile31(C), Gly37(I), Gly29(C),
Gly38(H), Gly29(B), Gly29(A), Val40(H), Lys28(B),
Val40(I), Val39(J) and Gly38(J) (Fig. 4). Here letters in
parentheses refer to chains shown in Figure S1 in SI. In
2BEG, Hoechst 33342 has 11 SC contacts with residues
Leu17(A), Gly38(B), Ala21(A), Asp23(A), Val24(A),
Leu34(A), Glu22(A), Val36(A), Val40(A), Phe19(A),
Val40(B) and Hoechst 34580 forms 9 contacts with resi-
dues Leu34(A), Asp23(A), Ala21(A), Val36(A), Phe19(A),
Gly38(B), Val40(B), Val40(A), Leu17(A) (Fig. 4). Both
DNA dyes have 9 SC contacts with 2M4J including the one
with the charged residue Lys28(A) (Fig. 4). Because both
ligands at the same place in 2MXU, they have 6 SC con-
tacts with residues Val12(A), Leu17(A), His14(A),
Gly33(A), Ile32(A), Leu34(A).
It should be noted that Hoechst 34580 and Hoechst
33342 prefer to stay next to hydrophobic residues of four
targets (Fig. 4). In 2LMN and 2M4J they have only one
contact with the positively charged residue Lys28 leading
to the dominant role of the vdW interaction over the
electrostatic interaction in stabilization of fibril-ligand
complexes (see below).
Blood brain barrier
Using PreADME, we have calculated log(BB) for ligands
revealed by the docking method as the top hits. Choosing
only those ligands which have log(BB)[ 0 one can further
reduce the set to 36 ligands for 2LMN, 11 ligands for
2BEG and 13 ligands for 2MXU (Fig. 1). Hoechst 34580
and Hoechst 33342 are capable to easily cross BBB having
log(BB) = 0.73 and 0.67, respectively.
Steered molecular dynamics
Using the Caver 3.0 [52] one can obtain several possible
pulling directions but the easiest pathway with the lowest
rupture force Fmax [50] was chosen. Two representative
optimal directions are shown in Figure S4 for ligands
inside receptor 2MXU and between layers of 2LMN. For
each ligand five independent SMD runs were performed
and the results were averaged over all trajectories. Typical
force–time curves are presented in Fig. 5 showing the
sensibility of rupture force on SMD runs.
For receptor 2MXU, the SMD method was applied to
study the binding affinity of 13 top leads including two
DNA dyes. The SMD and docking results are shown in
Table S3 together with ligand structures. The ranking of
binding affinities based on docking energies is different
from that predicted by SMD. Hoechst 34580 is champion
in SMD but it is fourth in docking. SMD predicts that
among 13 top hits compound CID 447767 is the weakest
binder having the lowest rupture force. Consistent with the
docking results, Hoechst 34580 and Hoechst 33342 have
nearly the same rupture force Fmax (Table S3).
For receptor 2LMN, keeping only those ligands which
have Fmax exceeding 470 pN the set of 36 ligands was
reduced to 15 compounds as the top leads for AD including
Hoechst 34580 and Hoechst 33342 (Table S4). As expected
the ranking by docking binding energy is different from the
SMD one. Compound CID 5327177 which is strongest in
docking becomes seventh in SMD, while CID 6083166
twelfth in docking is first by SMD. Having applied the
SMD method to 11 top leads bound with 2BEG we
obtained the results shown in Table S5. In SMD Hoechst
34580 and Hoechst 33342 are at positions 10 and 7,
respectively.
As evident from Tables S3-S5, in addition to Hoechst
34580 and Hoechst 33342, compound CID 447767 tightly
binds to three models of Ab40 and Ab42 fibril. Thus, we
predict that 3 compounds can interfere with both Ab40 and
Ab42 aggregation.
MM-PBSA results
To make a direct comparison with experiments, we used
the MM-PBSA method to compute DGbind of Hoechst
34580 and Hoechst 33342 using Eq. (1). The conforma-
tions obtained in the best docking mode (Fig. 3) were used
as starting conformations for all-atom MD simulation. For
each fibril-ligand complex we performed four 100-150 ns
MD runs starting from the same initial conformation but
644 J Comput Aided Mol Des (2016) 30:639–650
123
different random seed numbers. From the time dependence
of Ca root mean square displacement (RMSD) of Ab fibril,
it is evident that all complexes reach equilibrium after
about 40–100 ns (Figures S5 and S6 in SI). Snapshots
stored every 20 ps in equilibrium were used to estimate the
binding free energy given by Eq. (1).
For all studied targets, the vdW interaction dominates
over the electrostatic interaction in directing ligand binding
to Ab because both DGelec and DGvdW are negative but the
absolute value of DGvdW is larger than DGelec (Table 1).
The reason behind this is that, as mentioned above, the
DNA dyes locate rather close to hydrophobic residues than
Fig. 4 A HBs (green dashed
line) and side chain non-bonded
contacts (represented by an arc
with spokes radiating towards
the ligand atoms they contact)
between four fibrils and DNA
dyes Hoechst 34580 and
Hoechst 33342. The plot was
prepared using
LigPlot ? version 1.4.4 [57]
J Comput Aided Mol Des (2016) 30:639–650 645
123
to the charged ones (Fig. 4). Due to geometrical similarity
of Hoechst 34580 and Hoechst 33342 the entropic contri-
butions are nearly the same for all complexes (Table 1).
For a given target including 2BEG, 2M4J and 2MXU the
binding free energies of two ligands are the same within
error bars. The situation is different for 2LMN where
Hoechst 34580 shows binding affinity higher than that of
Hoechst 33342. The departure of this target from others is
presumably caused by the fact that the DNA dyes are
positioned next to the charged residue Lys28(B) (Fig. 4) in
2LMN but it is not the case for other targets where the
ligands are surrounded by non-charged residues. This is
also supported by the pronounced difference in electro-
static contributions of Hoechst 34580 and Hoechst 33342
to the binding propensity to 2LMN (Table 1).
The difference in binding free energies of two DNA
dyes to 2M4J was also seen (Table 1) due to contact with
positively charged residue Lys28, but it is not as pro-
nounced as in 2LMN because the ligands are positioned
outside fibril (Fig. 3). Finally, Hoechst 34580 and Hoechst
33342 show the lowest binding affinity to 2M4J (Table 1)
presumably because they are not located inside fibril.
However, this is valid for a single fibril. There is also a
possibility that DNA dyes interfere with the association
between fibrils before acting at the individual fibril level.
Then the interaction with 2M4J may get enhanced because
they can be considered as located inside fibrils. This issue
calls for further investigation.
In agreement with the docking simulations, SMD and
experimental results (see below), within the error bars
DGbind of both dyes are the same for Ab42 fibril. Having
DGbind\-10 kcal/mol for all targets, Hoechst 34580 and
Hoechst 33342 are expected to block the Ab40 and Ab42
aggregation.
In order to shed more light on the binding mechanisms,
we divided Hoechst 34580 and Hoechst 33342 into five
blocks (Figure S7 in SI). The first four blocks are similar
and the difference is in blocks 5 with the last atoms 55–62
for Hoechst 33342 and 55–63 for Hoechst 34580.
The contributions from 5 blocks to the vdW interactions
depend on targets but for a given target they are similar for
two dyes (Tables S6–S9 and Figure S8). The contribution
Fig. 5 Force-time profiles obtained by the SMD method in five independent trajectories for 2LMN-Hoechst 34580 and 2MXU- Hoechst 33342
complexes
Table 1 Binding free energy
(kcal/mol), obtained by MM-
PBSA method, for Hoechst
34580 and Hoechst 33342 using
the AMBER-f99SB-ILDN force
field
Receptor Complex DGelec DGvdW DGPB DGsur TDS DGbind
2LMN Hoechst 34580 -14.94 -61.94 31.56 -7.47 -25.87 -26.93 ± 1.89
Hoechst 33342 -8.28 -58.66 32.47 -5.60 -23.30 -16.77 ± 2.43
2M4J Hoechst 34580 -10.66 -41.19 23.26 -4.56 -23.07 -10.07 ± 6.24
Hoechst 33342 -8.00 -36.33 14.19 -5.76 -21.81 -14.08 ± 2.27
2BEG Hoechst 34580 -3.89 -49.78 15.51 -7.11 -21.61 -23.66 ± 4.47
Hoechst 33342 -10.92 -51.31 22.68 -5.43 -22.91 -22.08 ± 5.73
2MXU Hoechst 34580 -4.65 -65.32 29.06 -5.89 -23.21 -23.59 ± 1.12
Hoechst 33342 -4.51 -52.23 21.43 -8.38 -23.11 -20.57 ± 4.37
Results were averaged over 4 MD trajectories
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of block 5 is less important than other blocks because it has
the least number of atoms (8 and 9 atoms for Hoechst
33342 and Hoechst 34580, respectively). Block 4 con-
tributes to the vdW interactions less than blocks 1–3 and
this holds for all fibril models (Tables S6–S9).
Although contributions of individual blocks to the
electrostatic interactions are highly diverse, for all targets
the difference between Hoechst 34580 and Hoechst 33342
is most pronounced for block 5 (Tables S6–S9 and Fig-
ure S9). In 2LMN the Coulomb interaction between block
5 and Hoechst 33342 is 2.78 kcal/mol but it is
-24.49 kcal/mol for Hoechst 34580 (Table S6). Due to the
proximity with block 5 the difference between two ligands
in electrostatic interactions of block 4 is more than blocks
1–3.
Atoms 26, 29, 30, 37, 42 and 43 play a crucial role in
electrostatic interaction of Hoechst 34580 with 2LMN
having DEelec\-30 kcal/mol (Figure S9), while for
Hoechst 33342 atoms 24, 26, 29, 30, 38, 42, 43 and 56 are
vital. In 2BEG atoms 26, 29, 30, 37, 42 and 43 make a
major contribution for Hoechst 33342, whereas atoms 24,
26, 29, 30, 38, 42 and 43 of Hoechst 34580 are dominating.
Atoms 29, 30, 42 and 43 drive the electrostatic interaction
of two dyes with all four targets including (Figure S9).
Block 3 of Hoechst 33342 is superior in Coulomb
interaction with 2LMN, 2M4J and 2MXU while for 2BEG
block 2 is the most important (Tables S6–S9). For Hoechst
34580 block 2 tightly binds to 2LMN and 2M4J, but for
2BEG and 2MXU block 1 is dominating.
The contributions of individual blocks to the total
interaction (vdW and electrostatic) are shown in
Tables S6–S9 and Figure S10. For Hoechst 33342 block 3
is dominating for targets 2LMN, 2M4J and 2MXU but in
2BEG block 2 is the most prominent. Block 5 of Hoechst
34580 is the most important for 2LMN and 2M4J, while
block 1 and 3 have the highest binding propensity to 2BEG
and 2MXU.
Upon binding of Hoechst 33342 and Hoechst 34580 the
solvent accessible surface area (SASA) of all complexes
shrinks leading to the negative value of DGsur (Table 1).
The impact of the dyes depends on targets that Hoechst
34580 changes SASA of 2LMN and 2BEG to a larger
extent than Hoechst 33342, while the opposite effect occurs
in 2M4J and 2MXU.
Experimental results
Inhibition of Ab42 aggregation by Hoechst 34580
and Hoechst 33342
To evaluate the inhibitory effect of these compounds
against Ab42 aggregation, a Thioflavin T (ThT) assay was
performed to monitor Ab fibril formation while
respectively co-incubating with various concentrations of
the compounds (Fig. 6a, b). When ThT bound to cross b-
sheets of fibrils, its emission fluorescence intensity could
Fig. 6 Fibrillization kinetics of Ab42 incubated with and without
Hoechst 34580 or Hoechst 33342. a Various concentrations
(0.01–100 lM) of Hoechst 34580 was incubated with 50 lM Ab42
at 37 C for 70 h; b Various concentrations (0.01–100 lM) of
Hoechst 33342 was incubated with 50 lM Ab42 at 37 C for 70 h;
c Variation in ThT fluorescence intensity as a function of Hoechst
34580 (solid line) and Hoechst 33342 (dashed line). The data were
subtracted to background from compound alone. Data were analyzed
using GraphPad Prism to obtain IC50 values using log (inhibitor)
versus normalized response-variable slope. Dose–response curves
showed fractional binding of 5 lM ThT to 50 lM Ab42 fibrils in the
presence of Hoechst 34580 or Hoechst 33342, respectively
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be measured which indicates the quantity of relative fibril
formation. 50 lM Ab42 solutions co-incubated with 100,
25, 12.5, 3.125, 0.78, and 0.1, 0.01 lM Hoechst 34580 or
Hoechst 33342 at 37 C for 70 h. We found that these
compounds could inhibit the aggregation of Ab42 in a
dose-dependent manner. And then we examined the half-
maximal concentration (IC50) required (Fig. 6c) to com-
pare the potency of these three compounds. The IC50 was
obtained by measuring the concentration of Hoechst 34580
and Hoechst 33342 respectively while maintaining the
Ab42 concentration which gave 0.86 ± 0.05 lM for
Hoechst 34580 and 0.68 ± 0.05 lM for Hoechst 33342.
To compare the experimental results with the simulation
results one cannot use the binding free energy obtained for
2BEG (5Ab17-42) because this structure is based on H/D
exchange and therefore, is not an experimentally observed
structure. However, in vitro results may be compared with
the results obtained for the solid state NMR structure
8Ab11-42 (2MXU). With the equation DGbind = RT
ln(IC50), where gas constantR ¼ 1:987  103kcal K1mol1,
T = 300 K and inhibition constant IC50 is measured in
mol, a binding constant of 1 nM corresponds to
DGbind & -12.8 kcal/mol. A change in IC50 of one order
of magnitude results in a change in the binding free energy
of 1.4 kcal/mol. Therefore, the calculated values of DGbind
for 2MXU (Table 1) imply that IC50 of both DNA dyes
could be much less than 1 pM. They are also too far away
from the experimentally measured value. The reason
behind the discrepancy between theory and experiment is
that it is very hard to match the calculated absolute binding
free energy with experiments as it depends not only on
force fields [53] but also on theoretical methods [59].
However, theoretically estimated binding free energies are
presumably useful for ranking binding affinities [59]. This
is also evident from our results that, in agreement with
experiments, within the error bars Hoechst 34580 and
Hoechst 33342 have the same binding free energy
(Table 1). Therefore, our theoretical results on DGbind are
useful for prediction of binding affinity ranking rather than
for a direct comparison with experimentally measured
inhibition constants.
Conclusion
Using the multi-step virtual screening we have predicted
several compounds as potential drugs for AD. The ability
of Hoechst 34580 and Hoechst 33342 in blocking Ab
aggregation was confirmed also by in vitro experiments.
These compounds are located next to hydrophobic residues
of Ab peptides. The vdW interaction is dominating over
the electrostatic interaction in binding propensity. The
QSAR analysis showed that Hoechst 34580 and Hoechst
33342 can easily cross BBB having log(BB) greater than
0.5. Because these DNA dyes are known to be not cyto-
toxic they are recommended for further in vivo studies.
Future directions
In collaboration with experimentalists, our future work will
be focused on in vivo study of the impact of DNA dyes
Hoechst 34580 and Hoechst 33342 on Ab aggregation. We
plan also to search for new potential inhibitors from other
large databases.
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